$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000092706618000030 Filed on February 23, 2018

Income Statement

Concept	2017 Q4	2016 Q4	2016 Q3
Revenue	$2.781B	$2.699B	$2.725B
YoY Change	3.02%	-23.61%	-22.7%
Cost Of Revenue	$1.942B	-$519.4M	$2.698B
YoY Change	-473.84%	-120.65%	7.86%
Gross Profit	$839.2M	$197.5M	$1.033B
YoY Change	324.91%	-80.61%	0.8%
Gross Profit Margin	30.18%	7.32%	37.9%
Selling, General & Admin	$259.8M	-$105.6M	$410.7M
YoY Change	-346.02%	-125.91%	15.37%
% of Gross Profit	30.96%	-53.47%	39.76%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$184.0M	$188.8M	$181.8M
YoY Change	-2.54%	15.62%	12.15%
% of Gross Profit	21.93%	95.59%	17.6%
Operating Expenses	$404.1M	-$127.5M	$592.4M
YoY Change	-416.94%	-122.33%	14.34%
Operating Profit	$150.3M	$363.4M	$813.1M
YoY Change	-58.64%	48.38%	59.63%
Interest Expense	-$112.2M	-$92.00M	-$100.4M
YoY Change	21.96%	-3.87%	-0.3%
% of Operating Profit	-74.63%	-25.31%	-12.35%
Other Income/Expense, Net	$5.500M	-$600.0K	$1.876M
YoY Change	-1016.67%	-113.04%	-24.96%
Pretax Income	$46.83M	$259.7M	$710.2M
YoY Change	-81.97%	77.48%	73.92%
Income Tax	$101.7M	$65.80M	$104.3M
% Of Pretax Income	217.19%	25.34%	14.69%
Net Earnings	$303.4M	$157.7M	$571.3M
YoY Change	92.36%	-2728.77%	164.66%
Net Earnings / Revenue	10.91%	5.84%	20.96%
Basic Earnings Per Share	$1.66	$0.81	$2.80
Diluted Earnings Per Share	$1.64	$0.80	$2.76
COMMON SHARES
Basic Shares Outstanding	183.3M shares	197.4M	203.8M shares
Diluted Shares Outstanding			207.0M shares

Balance Sheet

Concept	2017 Q4	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$578.8M	$1.012B	$1.615B
YoY Change	-42.8%	-41.92%	-19.28%
Cash & Equivalents	$508.2M	$674.8M	$913.5M
Short-Term Investments	$70.53M	$337.0M	$701.1M
Other Short-Term Assets	$112.1M	$99.51M	$177.0M
YoY Change	12.61%	-47.71%	-58.74%
Inventory	$181.8M	$160.4M	$201.0M
Prepaid Expenses	$104.7M	$96.82M
Receivables	$1.715B	$1.504B	$1.850B
Other Receivables	$399.3M	$288.2M	$461.0M
Total Short-Term Assets	$8.771B	$3.995B	$4.261B
YoY Change	119.56%	-11.29%	-10.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.149B	$2.864B	$3.045B
YoY Change	9.95%	2.7%	16.14%
Goodwill	$6.610B	$6.015B	$9.383B
YoY Change	9.89%	2.02%	-1.1%
Intangibles	$113.8M	$73.50M	$1.576B
YoY Change	54.86%	-95.64%
Long-Term Investments	$0.00	$0.00	$617.0M
YoY Change		-100.0%	290.51%
Other Assets	$47.29M	$33.86M	$42.98M
YoY Change	39.67%	-53.97%	-31.1%
Total Long-Term Assets	$10.20B	$14.76B	$14.66B
YoY Change	-30.87%	5.35%	3.58%
TOTAL ASSETS
Total Short-Term Assets	$8.771B	$3.995B	$4.261B
Total Long-Term Assets	$10.20B	$14.76B	$14.66B
Total Assets	$18.97B	$18.76B	$18.93B
YoY Change	1.17%	1.3%	0.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$509.1M	$456.6M	$498.4M
YoY Change	11.5%	-11.15%	2.15%
Accrued Expenses	$616.0M	$977.0M	$846.0M
YoY Change	-36.95%	9.16%	1.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$178.0M	$160.0M	$153.0M
YoY Change	11.25%	24.03%	33.04%
Total Short-Term Liabilities	$3.068B	$2.711B	$2.639B
YoY Change	13.15%	13.0%	9.5%
LONG-TERM LIABILITIES
Long-Term Debt	$9.158B	$8.945B	$8.972B
YoY Change	2.38%	-0.62%	-1.21%
Other Long-Term Liabilities	$365.3M	$317.4M	$420.9M
YoY Change	15.11%	-27.74%	3.67%
Total Long-Term Liabilities	$365.3M	$317.4M	$420.9M
YoY Change	15.11%	-27.74%	3.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.068B	$2.711B	$2.639B
Total Long-Term Liabilities	$365.3M	$317.4M	$420.9M
Total Liabilities	$13.08B	$12.93B	$12.83B
YoY Change	1.12%	2.91%	0.23%
SHAREHOLDERS EQUITY
Retained Earnings	$3.634B	$3.710B	$5.079B
YoY Change	-2.06%	-14.84%	16.41%
Common Stock	$1.043B	$1.027B	$1.033B
YoY Change	1.53%	-8.15%	-6.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00	$1.148B
YoY Change		-100.0%	170.3%
Treasury Stock Shares			$16.56M
Shareholders Equity	$4.690B	$4.648B	$4.912B
YoY Change
Total Liabilities & Shareholders Equity	$18.97B	$18.76B	$18.93B
YoY Change	1.17%	1.3%	0.16%

Cashflow Statement

Concept	2017 Q4	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	$303.4M	$157.7M	$571.3M
YoY Change	92.36%	-2728.77%	164.66%
Depreciation, Depletion And Amortization	$184.0M	$188.8M	$181.8M
YoY Change	-2.54%	15.62%	12.15%
Cash From Operating Activities	$480.7M	$506.6M	$535.7M
YoY Change	-5.11%	16.01%	-21.1%
INVESTING ACTIVITIES
Capital Expenditures	-$265.5M	-$253.9M	$216.6M
YoY Change	4.57%	3.3%	26.42%
Acquisitions
YoY Change
Other Investing Activities	$6.200M	$309.4M	-$282.4M
YoY Change	-98.0%	-39.85%	790.85%
Cash From Investing Activities	-$259.2M	$55.50M	-$499.0M
YoY Change	-567.03%	-79.34%	145.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-236.5M	-544.0M	-404.4M
YoY Change	-56.53%	115.1%	11.96%
NET CHANGE
Cash From Operating Activities	480.7M	506.6M	535.7M
Cash From Investing Activities	-259.2M	55.50M	-499.0M
Cash From Financing Activities	-236.5M	-544.0M	-404.4M
Net Change In Cash	-15.00M	18.10M	-367.7M
YoY Change	-182.87%	-96.0%	-420.58%
FREE CASH FLOW
Cash From Operating Activities	$480.7M	$506.6M	$535.7M
Capital Expenditures	-$265.5M	-$253.9M	$216.6M
Free Cash Flow	$746.2M	$760.5M	$319.1M
YoY Change	-1.88%	11.43%	-37.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	182000000	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	12400000000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2017	dei	Trading Symbol TradingSymbol	DVA
CY2016Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	117547000	USD
CY2017Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	150512000	USD
CY2015	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	638024000	USD
CY2016	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	720252000	USD
CY2017	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	777485000	USD
CY2015	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-9293000	USD
CY2016	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-17766000	USD
CY2017	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-28925000	USD
CY2015	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	3997000	USD
CY2016	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	0	USD
CY2017	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	0	USD
CY2015	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	331000	USD
CY2016	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	232000	USD
CY2017	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	203000	USD
CY2017	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	2692000	USD
CY2017	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	-746000	USD
CY2016Q4	dva	Current Liabilities Excluding Held For Sale CurrentLiabilitiesExcludingHeldForSale	1903731000	USD
CY2017Q4	dva	Current Liabilities Excluding Held For Sale CurrentLiabilitiesExcludingHeldForSale	1856107000	USD
CY2015	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	456452000	USD
CY2015	dva	Debt Refinancing And Redemption Charges DebtRefinancingAndRedemptionCharges	48072000	USD
CY2016	dva	Debt Refinancing And Redemption Charges DebtRefinancingAndRedemptionCharges	0	USD
CY2017	dva	Debt Refinancing And Redemption Charges DebtRefinancingAndRedemptionCharges	0	USD
CY2015	dva	Debt Refinancing Charge DebtRefinancingCharge	48072000	USD
CY2016	dva	Debt Refinancing Charge DebtRefinancingCharge	0	USD
CY2017	dva	Debt Refinancing Charge DebtRefinancingCharge	0	USD
CY2016Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	25197000	USD
CY2017Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	19705000	USD
CY2016Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	79861000	USD
CY2017Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	63951000	USD
CY2015	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	0.000
CY2016	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	-0.099
CY2017	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	-0.002
CY2015	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0.000
CY2017Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	759732000	USD
CY2016Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9792928000	USD
CY2017Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10009590000	USD
CY2017Q4	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	98015000	USD
CY2017	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y1M12D
CY2015	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	123957000	USD
CY2016	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	64956000	USD
CY2017	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	61978000	USD
CY2016	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0.000
CY2017	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0.064
CY2015	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	19689000	USD
CY2016	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	12731000	USD
CY2017	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	7717000	USD
CY2015	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2016	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2017	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2015	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-493775000	USD
CY2016	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	0	USD
CY2017	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	526827000	USD
CY2015	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-32761000	USD
CY2016	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	54038000	USD
CY2017	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	117154000	USD
CY2016Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	3618000	USD
CY2017Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	3508000	USD
CY2015	dva	Investment And Other Asset Impairment InvestmentAndOtherAssetImpairment	0	USD
CY2016	dva	Investment And Other Asset Impairment InvestmentAndOtherAssetImpairment	14993000	USD
CY2017	dva	Investment And Other Asset Impairment InvestmentAndOtherAssetImpairment	295234000	USD
CY2016Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	855066000	USD
CY2015	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	0	USD
CY2016	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	404165000	USD
CY2017	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	23402000	USD
CY2015	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	213906000	USD
CY2016	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	866769000	USD
CY2017	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	660752000	USD
CY2017Q4	dva	Number Of Entities That Third Parties Held Non Controlling Equity Interests NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests	589	entity
CY2016	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	423000	USD
CY2017	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	220000	USD
CY2015	dva	Patient Care Costs PatientCareCosts	6856062000	USD
CY2016	dva	Patient Care Costs PatientCareCosts	7431582000	USD
CY2017	dva	Patient Care Costs PatientCareCosts	7640005000	USD
CY2015	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	97032000	USD
CY2016	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-126558000	USD
CY2017	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-250062000	USD
CY2017	dva	Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.01
CY2017	dva	Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.03
CY2017	dva	Percentage Of Risk On Revenue PercentageOfRiskOnRevenue	0.01
CY2015	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	619698000	USD
CY2016	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-124442000	USD
CY2017	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	154848000	USD
CY2015	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	18965000	USD
CY2016	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	13628000	USD
CY2017	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	44966000	USD
CY2017Q4	dva	Stock Repurchase Program Additional Authorized Amount StockRepurchaseProgramAdditionalAuthorizedAmount	1252961000	USD
CY2017	dva	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit	-251510000	USD
CY2017Q4	dva	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Liability TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability	0	USD
CY2016	dva	Unrecognized Tax Benefits Increase Resulting From Tax Cuts And Jobs Act Of2017 UnrecognizedTaxBenefitsIncreaseResultingFromTaxCutsAndJobsActOf2017	0	USD
CY2017	dva	Unrecognized Tax Benefits Increase Resulting From Tax Cuts And Jobs Act Of2017 UnrecognizedTaxBenefitsIncreaseResultingFromTaxCutsAndJobsActOf2017	3731000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	456619000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	509116000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1503950000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1714750000	USD
CY2016Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	23643000	USD
CY2017Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	28317000	USD
CY2016Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	76857000	USD
CY2017Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	64924000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2698276000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3103662000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-89643000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13235000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1027182000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1042899000	USD
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1129790000	USD
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	930362000	USD
CY2017	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1076894000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	238897000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	218399000	USD
CY2016	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-12837000	USD
CY2017	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-20498000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18625000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	20103000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24293000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19185000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14552000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15782000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1365000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2523000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4350000	shares
CY2016Q4	us-gaap	Assets Assets	18755776000	USD
CY2017Q4	us-gaap	Assets Assets	18948193000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3994748000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	8744358000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	960956000	USD
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5761642000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	31197000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38895000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	3701000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	8416000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	29997000	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	37695000	USD
CY2016Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	429039000	USD
CY2017Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	473489000	USD
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	5.22
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	4.81
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	5.14
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	4.74
CY2016	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	1052700000	USD
CY2017	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	907443000	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11076750000	USD
CY2017	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11005330000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	2950000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	6388000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11466	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	292252000	USD
CY2017Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	297170000	USD
CY2016Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	263438000	USD
CY2017Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	257772000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	407661000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	35258000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	33004000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	32578000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	36689000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	36038000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	234094000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	110491000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	297170000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	736897000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1244917000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	674776000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	508234000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	533875000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-585929000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-225285000	USD
CY2015	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-121893000	USD
CY2016	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-430917000	USD
CY2017	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-232329000	USD
CY2015	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	365138000	USD
CY2016	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	287049000	USD
CY2017	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	351557000	USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	194554491	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182462278	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	194554491	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	182462278	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	195000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	182000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	234923000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	850057000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	766496000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	157678000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	153398000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	166935000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	392601000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1003455000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	933431000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	429037000	USD
CY2017Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	576651000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	8845479000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	8677757000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	9063879000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	124503000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	322940000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	330191000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	856000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1928000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3422000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	145801000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	369393000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	380841000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20442000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	44525000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	47228000	USD
CY2016Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	270298000	USD
CY2017Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	292370000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9184799000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9400182000	USD
CY2017	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0470
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	71016000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	88412000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-98760000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	430000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2486000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4431000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	61744000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52010000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-395217000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	530869000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	927100000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	687430000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	486247000	USD
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	61709000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	95936000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	61529000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12464000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	23762000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	141919000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	100376000	USD
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	62368000	USD
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-56982000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-9737000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-28530000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	37347000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	452247000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	262465000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	396231000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	201183000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	128813000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	108429000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	73525000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	37794000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	224712000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	96537000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56016000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61282000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	530869000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	486247000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	676781000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	501763000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	463905000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	509497000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	559911000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	444720000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	494945000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	544129000	USD
CY2015	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.24
CY2016Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.34
CY2016Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.56
CY2016Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.11
CY2016Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.07
CY2016	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.75
CY2017Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.03
CY2017Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.13
CY2017Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.92
CY2017Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.79
CY2017	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.24
CY2015	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	88216000	USD
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.64
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.29
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.65
CY2016	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	24052000	USD
CY2017	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-364856000	USD
CY2016Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	5252135000	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2016Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2017Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2016Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2017Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.48
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.80
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.36
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.33
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.52
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.47
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.76
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.80
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.29
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.47
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2571000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4276000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	254000	USD
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.301
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.266
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.205
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.089
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.029
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.033
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.023
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.018
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	706564000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	616116000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0	USD
CY2016	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0	USD
CY2017	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	61166000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M12D
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	45749000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	28397000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	13473000	USD
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	28157000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	13251000	USD
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Asset Off Market Lease Favorable Gross FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross	7244000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Asset Off Market Lease Favorable Gross FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross	7623000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	342668000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	356774000	USD
CY2016Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	407220000	USD
CY2017Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	429140000	USD
CY2015	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	374374000	USD
CY2017	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	6273000	USD
CY2015	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-495000000	USD
CY2016	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2017	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	526827000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1031125000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1072841000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1064026000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	5896215000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	6015375000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	6610279000	USD
CY2016	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	198927000	USD
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	617032000	USD
CY2015	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	210234000	USD
CY2016	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	296408000	USD
CY2017	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	981589000	USD
CY2016	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-8816000	USD
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	46454000	USD
CY2017Q4	us-gaap	Goodwill Gross GoodwillGross	6680799000	USD
CY2017Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	70520000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4066000	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	28415000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	36196000	USD
CY2016	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	42536000	USD
CY2017	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	32386000	USD
CY2015	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1239703000	USD
CY2016	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1411415000	USD
CY2017	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1268362000	USD
CY2015	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	9155447000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	9727360000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	10093670000	USD
CY2015	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	8742542000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9296052000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9608272000	USD
CY2015	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	412905000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	431308000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	485398000	USD
CY2015	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	9982245000	USD
CY2016Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2607167000	USD
CY2016Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2675474000	USD
CY2016Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2725407000	USD
CY2016Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2699419000	USD
CY2016	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	10707467000	USD
CY2017Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2631251000	USD
CY2017Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2699399000	USD
CY2017Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2765071000	USD
CY2017Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2780913000	USD
CY2017	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	10876634000	USD
CY2016Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	305781000	USD
CY2017Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	42316000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	305781000	USD
CY2017Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	42316000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2017Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2015	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	323199000	USD
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1032373000	USD
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	901277000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	730249000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1278754000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1725822000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41862000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	344351000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-326036000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	688387000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	321959000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	331231000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.78
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.80
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2017	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.71
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	710246000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	259669000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1623105000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	775517000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	288060000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	289384000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	46825000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1399786000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	480877000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1191344000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1075927000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.53
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.83
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.84
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.69
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.74
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.12
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.29
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.79
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.81
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.86
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.78
CY2015	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.49
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.81
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.82
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.65
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.73
CY2016	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.04
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.26
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-53467000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-158262000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-245372000	USD
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-53467000	USD
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-71804000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-118443000	USD
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	20213000	USD
CY2016Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11772000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-152499000	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	6433000	USD
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-24520000	USD
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-370872000	USD
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.26
CY2017Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	143587000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-237659000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.58
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.11
CY2016Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.07
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.76
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.13
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.35
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.95
CY2017Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.80
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.26
CY2015	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	13919000	USD
CY2016	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	16874000	USD
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8640000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207510000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	431761000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323859000	USD
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	295726000	USD
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	455813000	USD
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-40997000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	156075000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	339411000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	387159000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	49440000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30998000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11897000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	26876000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	202867000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	152240000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	156305000	USD
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	41767000	USD
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	77376000	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-52176000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	54950000	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	68272000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-78239000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48313000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22920000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18625000	USD
CY2015	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	113470000	USD
CY2016	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	176494000	USD
CY2017	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1908000	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3723000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-35893000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	11945000	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	33354000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2190000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1070000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	529000	shares
CY2016Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1125000	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	245534000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	30517000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	11157000	USD
CY2017Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	33255000	USD
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	416172000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	470601000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73504000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	113827000	USD
CY2015	us-gaap	Interest And Debt Expense InterestAndDebtExpense	408380000	USD
CY2016	us-gaap	Interest And Debt Expense InterestAndDebtExpense	414116000	USD
CY2017	us-gaap	Interest And Debt Expense InterestAndDebtExpense	430634000	USD
CY2015	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	9723000	USD
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	12990000	USD
CY2017	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	19176000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	389755000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	394013000	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	406341000	USD
CY2015	us-gaap	Interest Paid InterestPaid	405120000	USD
CY2016	us-gaap	Interest Paid InterestPaid	406987000	USD
CY2017	us-gaap	Interest Paid InterestPaid	424547000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	82234000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	83362000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	160419000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	181799000	USD
CY2016Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	555893000	USD
CY2017Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	330516000	USD
CY2016Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	492039000	USD
CY2016Q4	us-gaap	Land Land	26339000	USD
CY2017Q4	us-gaap	Land Land	33814000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2495070000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2816675000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12932777000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13050767000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18755776000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18948193000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2710964000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3041177000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	807233000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1185070000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	428885000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3508338000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	178213000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1283671000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3307507000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	73362000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9158018000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	160262000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	178213000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8944676000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	37695000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-214476000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9104938000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9336231000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	303396000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	663618000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	157678000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	153208000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1351981000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-766257000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-881784000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1201668000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1366731000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	166937000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	74035000	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	28127000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1049091000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	29997000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1557200000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1963444000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1907449000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	269732000	USD
CY2017Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0488
CY2016Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	69000000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	6000000	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2182912000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2352246000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	336978000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	81211000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	306981000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	43516000	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	29997000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	37695000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	201694000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	196037000	USD
CY2015	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	508020000	USD
CY2016	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-570141000	USD
CY2017	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-166542000	USD
CY2015	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	25855000	USD
CY2016	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-15788000	USD
CY2017	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-58743000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-138970000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	97434000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	53382000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	571332000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	157726000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	447697000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	127001000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2016Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	6011000	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	48378000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	431129000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	422033000	USD
CY2017Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	5447000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	1136766000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	813103000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	363445000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	2029710000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	875928000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	391196000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	395294000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	150337000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	1812755000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3222505000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	446935000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	313005000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	351962000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	384764000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	422245000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1303594000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	440601000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	478531000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	530748000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	99510000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	112058000	USD
CY2016Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	2692000	USD
CY2017Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	7331000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33857000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47287000	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-23889000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-39614000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	99770000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-10087000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-34809000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29627000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	102876000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	690000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	360000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	377000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	423000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	220000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3111000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-2566000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-5058000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12241000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-3670000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-5437000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	99510000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1413000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1427000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3705000	USD
CY2016Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	583000	USD
CY2017Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	583000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	578892000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	552662000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	317383000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	365325000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-44691000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7338000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-66925000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8073000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7511000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17665000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	288156000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	372919000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	125860000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	83689000	USD
CY2017	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	803879000	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	549935000	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1097822000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	802949000	USD
CY2015	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	174635000	USD
CY2016	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	192401000	USD
CY2017	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	211467000	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8783000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13539000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13117000	USD
CY2015	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	96469000	USD
CY2016	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	563856000	USD
CY2017	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	803879000	USD
CY2015	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	17911000	USD
CY2016	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	27096000	USD
CY2017	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4816000	USD
CY2015	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1709883000	USD
CY2016	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1133192000	USD
CY2017	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	230989000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	707998000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829095000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	905250000	USD
CY2015	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	66382000	USD
CY2016	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	21512000	USD
CY2017	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5357000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	112058000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	96818000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	104727000	USD
CY2015	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	54644000	USD
CY2016	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	47590000	USD
CY2017	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	74552000	USD
CY2015	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	129000	USD
CY2016	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
CY2017	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	106000	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	54541988000	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	51991490000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50991960000	USD
CY2015	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2016	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2017	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2864000	USD
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-758668000	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1227539000	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-921105000	USD
CY2015	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2016	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2017	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1637358000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1240502000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	492470000	USD
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2058000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	18963000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	6408000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	14971000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	6408000	USD
CY2015	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2016	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	40920000	USD
CY2017	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	92336000	USD
CY2015	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	19715000	USD
CY2016	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	64725000	USD
CY2017	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	92336000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26155000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23543000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21252000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	427410000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5562397000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6252875000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2864121000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3149213000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9240000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11677000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7033000	USD
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	973258000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1011360000	USD
CY2017Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	0	USD
CY2015	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	53998962000	USD
CY2016	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	52116120000	USD
CY2017	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	50837112000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3710313000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3633713000	USD
CY2016Q4	us-gaap	Senior Notes SeniorNotes	4500000000	USD
CY2017Q4	us-gaap	Senior Notes SeniorNotes	4500000000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	56664000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	38338000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	35092000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7500000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	117260000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	73944000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34895000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	117722000	USD
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2628008	shares
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6648199	shares
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25609000	USD
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	62.78
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	67.92
CY2016Q3	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	247039000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4648047000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4690029000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4849741000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4886066000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1394000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2016	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	64.41
CY2017	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	62.54
CY2016	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	16649090	shares
CY2017	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	12966672	shares
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	575380000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1072377000	USD
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	810949000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39011000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24066000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32776000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	23382000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	2051000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2595000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	4195000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9714000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7606000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	804000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	8710000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1277000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1380000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5266000	USD
CY2017Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	870314000	USD
CY2017Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	475143000	USD
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216251807	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216252000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204904656	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204905000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191349000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191348533	shares
CY2015	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	214062000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	203835000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	190820000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	211868000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	211867714	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201641000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201641173	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188625559	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188626000	shares
CY2017	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, claims, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> suits, governmental investigations and audits (including investigations resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of December 31, 2017 and December 31, 2016, the Company’s total recorded accruals, including DMG, with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were approximately </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$69,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</font></div><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inquiries by the Federal Government and Certain Related Civil Proceedings</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 U.S. Office of Inspector General (OIG) Medicare Advantage Civil Investigation</font><font style="font-family:inherit;font-size:10pt;">: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of DMG, received a subpoena from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) requesting documents and information for the period from January 1, 2008 through December 31, 2013, for certain MA plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain MA plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the subpoena described above, in June 2015, the Company received a civil subpoena from the OIG covering the period from January 1, 2008 through the present and seeking production of a wide range of documents relating to the Company’s and its subsidiaries’ (including DMG’s and its subsidiary JSA’s) provision of services to MA plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into MA patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested includes information relating to patient diagnosis coding practices for a number of conditions, including potentially improper historical DMG coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012 acquisition of HealthCare Partners (now known as the Company's DMG business), and the Company notified CMS in April 2015 of the coding practice and potential overpayments. In that regard, the Company has identified certain additional coding practices which may have been problematic, some of which were the subject of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Swoben Private Civil Suit, </font><font style="font-family:inherit;font-size:10pt;">and is in discussions with the DOJ relating to those practices. The Company is cooperating with the government. In addition, the Company is continuing to review other DMG coding practices to determine whether there were any improper coding issues. In connection with the Company's acquisition of DMG in 2012, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company has submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intends to pursue recovery from the escrow. However, the Company can make no assurances that the indemnification and escrow will cover the full amount of the Company’s potential losses related to these matters. </font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Prescription Drug Investigation</font><font style="font-family:inherit;font-size:10pt;">: In early February 2016, the Company announced that its pharmacy services’ wholly-owned subsidiary, DaVita Rx, received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office for the Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as into the Company’s relationship with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues, including potential write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescription drugs related to DaVita Rx. The Company notified the government in September 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. Upon completion of its review, the Company filed a self-disclosure with the OIG in February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlap with information requested by the U.S. Attorney’s Office. The OIG informed the Company in February 2016 that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. In connection with the Company’s ongoing efforts working with the government the Company learned that a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint had been filed covering some of the issues in the CID and the Company’s self-disclosure. In December 2017, the Company finalized and executed a settlement agreement with the government and relators in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> matter and that included total monetary consideration of </font><font style="font-family:inherit;font-size:10pt;">$63,700</font><font style="font-family:inherit;font-size:10pt;">, as previously announced, of which </font><font style="font-family:inherit;font-size:10pt;">$41,500</font><font style="font-family:inherit;font-size:10pt;"> was an incremental cash payment and </font><font style="font-family:inherit;font-size:10pt;">$22,200</font><font style="font-family:inherit;font-size:10pt;"> was for amounts previously refunded, and all of which was previously accrued. The government’s investigation into the Company's relationship with pharmaceutical manufacturers is ongoing and the Company is continuing to cooperate with the government in this investigation.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney American Kidney Fund Investigation</font><font style="font-family:inherit;font-size:10pt;">: On January 4, 2017, the Company was served with an administrative subpoena for records by the United States Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covers the period from January 1, 2007 through the present, and seeks documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Company is cooperating with the government and is producing the requested information.</font></div><div style="line-height:120%;padding-top:13px;text-align:center;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* * </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. In addition to the inquiries and proceedings specifically identified above, the Company is frequently subject to other inquiries by state or federal government agencies and/or private civil </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, possible criminal penalties, any of which could have a material adverse effect on the Company.</font></div><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Claims</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." In November 2017, the court appointed the lead plaintiff and an amended complaint was filed on January 12, 2018. The Company's response is due March 13, 2018. The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">In re DaVita Inc. Stockholder Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated the three previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. An amended complaint was filed in September 2017, and on December 18, 2017 the Company filed a motion to dismiss and a motion to stay proceedings in the alternative. The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Resolved Matters</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Swoben Private Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On July 13, 2009, pursuant to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the FCA and the California False Claims Act, James M. Swoben, as relator, filed his initial </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. In April 2013, HealthCare Partners (HCP), now known as the Company’s DMG subsidiary, was one of several defendants served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), an HMO. The allegations in the complaint relate to alleged overpayments received from government healthcare programs, including allegations of violations of the federal FCA and the California False Claims Act and allegations against HCP relating to patient diagnosis coding. The complaint sought monetary damages and civil penalties as well as costs and expenses. On October 18, 2017, the relator filed a Notice of Dismissal of the action as to HCP, and the government consented to the dismissal, as a result of which the suit is now dismissed, without prejudice.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Solari Post-Acquisition Matter</font><font style="font-family:inherit;font-size:10pt;">: In 2016, HCP Nevada disclosed to the OIG for the HHS that proper procedures for clinical and eligibility determinations may not have been followed by Las Vegas Solari Hospice (Solari), which was acquired in March 2013 and sold in September 2016 by HCP Nevada. In June 2016, the Company was notified by the OIG that the disclosure submission had been accepted into the OIG’s Self Disclosure Protocol. HCP Nevada had previously made a disclosure and repayment of overpayments to National Government Services (NGS), the Medicare Administrative Contractor for HCP Nevada, for claims submitted by Solari to the federal government prior to DMG’s acquisition of Solari and claims made to the government post-acquisition for which the sellers had certain responsibilities pursuant to a management services agreement. In October 2017, the Company finalized and executed a settlement agreement with the OIG including payment of an immaterial amount.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2011 Suit against the U.S. Department of Veterans Affairs</font><font style="font-family:inherit;font-size:10pt;">: As previously disclosed, the Company had a pending lawsuit in the U.S. Court of Federal Claims against the federal government which was originally filed in May 2011. The lawsuit related to the U.S. Department of Veterans Affairs (VA) underpayment of dialysis services the Company provided from 2005 through 2011 to veterans pursuant to VA regulations. In the first quarter of 2017, the Company received a payment of </font><font style="font-family:inherit;font-size:10pt;">$538,000</font><font style="font-family:inherit;font-size:10pt;"> related to the settlement with the VA. The Company's consolidated entities recognized a net gain of </font><font style="font-family:inherit;font-size:10pt;">$527,000</font><font style="font-family:inherit;font-size:10pt;"> on this settlement. The Company's nonconsolidated and managed entities recognized a gain of </font><font style="font-family:inherit;font-size:10pt;">$9,000</font><font style="font-family:inherit;font-size:10pt;">, of which the Company's equity investment share was </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. The net effect was a net increase of </font><font style="font-family:inherit;font-size:10pt;">$530,000</font><font style="font-family:inherit;font-size:10pt;"> to the Company's operating income.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 U.S. Department of Justice Vascular Access Investigation and Related</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Qui Tam</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;"> </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Litigation</font><font style="font-family:inherit;font-size:10pt;">: In November 2015, the Company announced that RMS Lifeline, Inc., a wholly-owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a CID from the DOJ. The CID relates to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers in December 2012. Based on the language of the CID, the DOJ appeared to be looking at whether angiograms performed at the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides vascular access management services for dialysis patients. The Company cooperated with the government and produced the requested information. The DOJ investigation was initiated pursuant to a complaint brought under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the FCA (the Complaint). The Complaint was originally filed under seal in August 2014 in the U.S. District Court, Middle District of Florida, United States ex. rel James Spafford v. DaVita HealthCare Partners, Inc., et al., Case Number 6:14-cv-1251-Orl-41DAB, naming several doctors along with the Company as defendants. In December 2015, a First Amended Complaint was filed under seal. In May 2016, the First Amended Complaint was unsealed. The First Amended Complaint alleged violations of the FCA due to the submission of claims to the government for allegedly medically unnecessary angiograms and angiography procedures at the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> vascular access centers as well as employment-related claims. The Complaint covers alleged conduct dating from July 2008, prior to the Company’s acquisition of the centers, to the present. The DOJ declined to intervene. In January 2017, the Company finalized and executed a settlement agreement with the relator and the government for an immaterial amount, and in April 2017, the court dismissed the case with prejudice.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Vainer Private Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: As previously disclosed, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the federal FCA. The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and attorney fees and other costs of </font><font style="font-family:inherit;font-size:10pt;">$45,000</font><font style="font-family:inherit;font-size:10pt;"> which was paid in 2015.</font></div><div style="line-height:120%;padding-top:13px;text-align:center;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> * *</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than as described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 16, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, financial results or reputation.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.</font></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of goodwill and investments, accounting for income taxes, long-term variable compensation accruals, consolidation of variable interest entities, and certain fair value estimates. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0000927066-18-000030-index-headers.html	Edgar Link	pending
0000927066-18-000030-index.html	Edgar Link	pending
0000927066-18-000030.txt	Edgar Link	pending
0000927066-18-000030-xbrl.zip	Edgar Link	pending
centerbystateusmap.jpg	Edgar Link	pending
chart-9ecc61c6dd3f4c33d02.jpg	Edgar Link	pending
chart-a538f0decd05b0ea60e.jpg	Edgar Link	pending
chart-fbd8ce7f9e63038215c.jpg	Edgar Link	pending
davitalogorgbfa03.jpg	Edgar Link	pending
dva-123117x10k.htm	Edgar Link	pending
dva-123117xex1027.htm	Edgar Link	pending
dva-123117xex121.htm	Edgar Link	pending
dva-123117xex211.htm	Edgar Link	pending
dva-123117xex231.htm	Edgar Link	pending
dva-123117xex311.htm	Edgar Link	pending
dva-123117xex312.htm	Edgar Link	pending
dva-123117xex321.htm	Edgar Link	pending
dva-123117xex322.htm	Edgar Link	pending
dva-20171231.xml	Edgar Link	completed
dva-20171231.xsd	Edgar Link	pending
dva-20171231_cal.xml	Edgar Link	unprocessable
dva-20171231_def.xml	Edgar Link	unprocessable
dva-20171231_lab.xml	Edgar Link	unprocessable
dva-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2017 Q4 Form 10-K Financial Statement

#000092706618000030 Filed on February 23, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2017 Q4 Form 10-K Financial Statement

#000092706618000030 Filed on February 23, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva